Challenging cases in MDS MDT- from cytopenia to AML
Tracks
-
| Monday, April 28, 2025 |
| 8:00 AM - 9:30 AM |
| Carron 1 |
Details
We are planning to focus our entire session on MDT style-utilising case-based discussion and interactive questions. The cases and discussions will focus on genetic panels and its interpretation for referring haematologists, with emphasis on therapeutic approach available to haematologists in UK. The patient cases will cover management of low risk MDS after EPO failure, low risk MDS with high risk genetic/clinical features, iron chelation, beyond 5-azacytidine for high risk MDS and the blurring of boundaries between MDS & AML.
Speaker
Dr. Catherine Cargo
Consultant
St James's University Hospital
Genetic panel in MDS and cytopenia(s)- Clinical utility for UK physicians
Ms Amy Todd
Physician Associate
Leeds Teaching Hospitals NHS Trust
Genetic panel in MDS and cytopenia(s)- Clinical utility for UK physicians
Dr. Dominic Culligan
Consultant
Aberdeen Royal Infirmary
Lower risk but high risk MDS - How do we recognise this?
Dr Abhinav Mathur
Specialist Registrar
NHS Grampian
Lower risk but high risk MDS - How do we recognise this?
Dr Pramila Krishnamurthy
Consultant Haematologist
King's College Hospital NHS Foundation Trust
High risk MDS and MDS- Blurring of boundaries?
Dr. Richard Salisbury
Haematology Registrar
Oxford University Hospitals NHS Foundation Trust
High risk MDS and MDS- Blurring of boundaries?
Chair
Austin Kulasekararaj
Consultant Haematologist
King's College Hospital
